Post-marketing Surveillance of the Safety and Effectiveness of Rosiglitazone/Metformin in Korean Patients with Type 2 Diabetes
Journal of Korean Society for Clinical Pharmacology and Therapeutics
;
: 195-204, 2012.
Article
in Korean
| WPRIM
| ID: wpr-138495
ABSTRACT
BACKGROUND:
To evaluate the safety and effectiveness of rosiglitazone/metformin in patients with type 2 (non-insulin-dependent) diabetes.METHODS:
A total of 982 patients were enrolled by 19 physicians from November 2003 to November 2010. Patients treated with rosiglitazone/metformin at least once, were included in safety assessment. The incidences of adverse events (AEs) and serious adverse events (SAEs) were estimated. The effectiveness of rosiglitazone/metformin was evaluated through change in fasting blood glucose (FBG), 2-hour postprandial glucose (2hr PPG), Hemoglobin A1c (HbA1c).RESULTS:
Of the 982 patients, 713 patients with the mean age of 56.4 +/- 11.5 years were included in the safety assessment. A total of 130 AEs were reported from 110 patients (15.4 %). The most frequent AEs were upper respiratory infection (2.4 %), oedema (2.2 %), gastritis (1.3 %), and weight increase (1.1 %). The incidence of unexpected AEs was 5.9 % (42/713, 47 AEs). Three SAEs such as bacterial pneumonia, hyperglycaemia, chest pain were reported in 2 patients. As it is about effectiveness, patients showed statistically significant reductions after treatment of rosiglitazone/metformin in FBG, 2hr PPG, and HbA1c (P<0.001 by paired t-test, for all).CONCLUSION:
Our data suggest that rosiglitazone/metformin is well tolerated and effective in Korean patients with type 2 (non-insulin-dependent) diabetes.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood Glucose
/
Chest Pain
/
Hemoglobins
/
Incidence
/
Fasting
/
Pneumonia, Bacterial
/
Thiazolidinediones
/
Gastritis
/
Glucose
/
Metformin
Type of study:
Incidence study
/
Prognostic study
/
Screening study
Limits:
Humans
Language:
Korean
Journal:
Journal of Korean Society for Clinical Pharmacology and Therapeutics
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS